Download PDF
Semin Vasc Med 2002; 2(1): 109-120
DOI: 10.1055/s-2002-23101
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hypertension and Renal Complications in Type 2 Diabetes

Romano Nosadini
  • Department of Internal Medicine, Medical School, University of Sassari, Italy
Further Information

Publication History

Publication Date:
25 March 2002 (online)

    Permissions and Reprints

ABSTRACT

Diabetes mellitus and arterial hypertension are the leading causes of end-stage renal disease in industrialized countries. Although attention has focused on renal disease and insulin-dependent diabetes mellitus (type 1 diabetes), a silent epidemic of renal disease caused by type 2, noninsulin-dependent diabetes mellitus is rapidly developing. The course of renal function is heterogeneous in type 2 diabetic patients and reflects heterogeneous patterns of renal lesions. A subset of patients with microalbuminuria and proteinuria is characterized by the typical diabetic glomerulopathy usually observed in type 1 diabetic patients, with altered albumin excretion rate (AER), for example, glomerular basement membrane thickening and mesangial fractional volume expansion. These patients also have diabetic retinopathy and rapidly lose renal function despite tight blood pressure control.

In contrast, a second subset of type 2 diabetic patients has normal or near-normal patterns of glomerular structure, despite abnormalities of AER comparable to those of the patients with diabetic glomerulopathy. Thus abnormalities of AER have a different renal prognostic value depending on the underlying renal structure. The patients with worse clinical prognosis and typical diabetic glomerulopathy also have diabetic retinopathy, whereas those with a better course of renal function quite often have no diabetic retinopathy.

Several findings, albeit not unanimous, suggest that HbA1c levels above 7.5 to 8.0 % are closely associated with a rapid decay of renal function in type 2 diabetes. Tight blood pressure control plays a further important role in determining the progression of renal a damage in type 2 diabetes mellitus. Convincing evidence has been provided that drugs capable of inhibiting the renin-angiotensin hormonal system are quite effective in preventing and delaying the evolution of renal damage in both type 1 and 2 diabetes. Equally strong data support the view that other antihypertensive compounds such as beta-blockers and calcium antagonists also delay the progression of renal damage in diabetes mellitus. Whatever the drug used to treat hypertension, the majority of the authors conclude that blood pressure levels should be maintained below 130/85 mmHg in diabetic patients.

While it is well established that uncontrolled diabetes underlies the development of diabetic nephropathy, newer evidence suggests that genetically determined susceptibility to hyperglycemia-caused glomerular injury is also necessary. More information on this issue will help to design new therapeutical approaches to treat hypertension and renal complications in type 2 diabetes.

REFERENCES

  • 1 Ritz E, Rychlick I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes. A medical catastrophe of worldwide dimensions.  Am J Kidney Dis . 1999;  34 795-808
    PubMedGoogle Scholar
  • 2 Excerpts from US Renal Data System Annual 1998 Data Report. Am J Kidney Dis .  1998;  32 (suppl 1) S9-S141
    PubMedGoogle Scholar
  • 3 Catalano C, Postorino M, Kelly P. Diabetes mellitus and renal replacement therapy in Italy: prevalence, main characteristics and complications.  Nephrol Dial Transplant . 1990;  5 788-796
    PubMedGoogle Scholar
  • 4 The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med .  1997;  157 2413-2441
    PubMedGoogle Scholar
  • 5 Krolewski A S, Warram J H, Chriestlieb A R, Busick E J, Kahn C R. The changing natural history of nephropathy in type 1 diabetes.  Am J Med . 1985;  78 785-794
    CrossrefPubMedGoogle Scholar
  • 6 Humphrey L L, Ballard D J, Frohnert P P, Chu C P, O'Fallon M, Palumbo P J. Chronic renal failure in noninsulin-dependent diabetes mellitus: a population based study in Rochester Minnesota.  Ann Intern Med . 1985;  11 788-794
    PubMedGoogle Scholar
  • 7 Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with Type I or Type II diabetes mellitus.  Nephrol Dial Transplant . 1989;  4 859-863
    PubMedGoogle Scholar
  • 8 Kunzelman C L, Knowler W C, Petitt D J, Bennett P H. Incidence of nephropathy in type 2 diabetes mellitus in the Pima Indians.  Kidney Int . 1989;  35 681-687
    PubMedGoogle Scholar
  • 9 Fabre J, Balant L P, Dayer P G, Fox H M, Vernet A T. The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients.  Kidney Int . 1982;  21 730-738
    CrossrefPubMedGoogle Scholar
  • 10 Mogensen C E. Microalbuminuria as a predictor of clinical diabetic nephropathy.  Kidney Int . 1987;  31 673-689
    PubMedGoogle Scholar
  • 11 Golini A. Demografia dell'invecchiamento. In: Crepaldi G ed. Trattato. di Gerontologia E Geriatria Torino Italy: UTET 1993
    Google Scholar
  • 12 Shaw N J. Noninsulin-dependent diabetes in children-a commentary.  Pract Diab Int . 2001;  18 3-4
    CrossrefPubMedGoogle Scholar
  • 13 Ditscherlein G. Nierenveranderungen bei Diabetikern.  Jena Germany: Gustav Fisher Verlag 1969
    Google Scholar
  • 14 Olsen S, Mogensen C E. How often is NIDDM complicated with nondiabetic renal disease: an analysis of renal biopsies the literature.  Diabetologia . 1996;  39 1638-1645
    CrossrefPubMedGoogle Scholar
  • 15 Hayashi H, Karasawa R, Inn H. An electron microscopic study of glomeruli in Japanese patients with noninsulin-dependent diabetes mellitus.  Kidney Int . 1992;  41 749-757
    PubMedGoogle Scholar
  • 16 Pagtulanan M E, Miller P L, Jumping-Eagle S. Podocyte loss progressive glomerular injury in type 2 diabetes.  J Clin Invest . 1997;  99 342-348
    PubMedGoogle Scholar
  • 17 Nosadini R, Velussi M, Brocco E. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.  Diabetes . 2000;  49 476-484
    CrossrefPubMedGoogle Scholar
  • 18 Fioretto P, Mauer M, Brocco E. Patterns of renal injury in NIDDM patients with microalbuminuria.  Diabetologia . 1996;  39 1569-1576
    CrossrefPubMedGoogle Scholar
  • 19 Osterby R, Gall M-A, Shmitz A, Nielsen F S, Nyberg G, Parving H-H. Glomerular structure function in proteinuric Type 2 (noninsulin-dependent) diabetic patients.  Diabetologia . 1993;  36 1064-1074
    PubMedGoogle Scholar
  • 20 Brocco E, Fioretto P, Mauer M, Saller A, Nosadini R. Renal structure function in noninsulin-dependent diabetic patients with microalbuminuria.  Kidney Int . 1997;  52 S40-S44
    PubMedGoogle Scholar
  • 21 Christensen P, Larsen S, Horn T, Olsen S, Parving H-H. Cases of albuminuria in patients with type 2 diabetes without diabetic retinopathy.  Kidney Int . 2000;  58 1719-1731
    CrossrefPubMedGoogle Scholar
  • 22 Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogeneous nature of renal lesions in type II Diabetes.  J Am Soc Nephrol . 1993;  3 1458-1466
    PubMedGoogle Scholar
  • 23 Mauer S. Structural functional correlations of diabetic nephropathy.  Kidney Int . 1994;  45 612-622
    PubMedGoogle Scholar
  • 24 Pinel N, Fadel B, Bilous R W, Corticelli P, Cordonnier D, Halimi S. Renal biopsies in NIDDM patients with micro-macroproteinuria:heterogeneity of renal lesions.  Diabetologia . 1995;  38 A217
    PubMedGoogle Scholar
  • 25 United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet . 1998;  352 854-866
    CrossrefPubMedGoogle Scholar
  • 26 United Kingdom Prospective Diabetes Study (UKPDS) GroupM. Tight blood pressure control risk of macrovascular microvascular complications in type 2 diabetes (UKPDS 38).  Br Med J . 1998;  317 703-713
    PubMedGoogle Scholar
  • 27 Stratton I, Adler A, Neil W. Association of glycemia with macrovascular microvascular complications of type 2 diabetes: prospective observational study (UKPDS 35).  Br Med J . 2000;  321 405-411
    CrossrefPubMedGoogle Scholar
  • 28 Adler A, Stratton I, Neil W AH. Association of systolic blood pressure with macrovascular microvascular complications of type 2 diabetes: prospective observational study (UKPDS 35).  Br Med J . 2000;  321 412-419
    CrossrefPubMedGoogle Scholar
  • 29 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular microvascular outcomes in people with diabetes mellitus: results of the HOPE study MICRO-HOPE substudy.  Lancet . 2000;  355 253-259
    CrossrefPubMedGoogle Scholar
  • 30 Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensified treatment of diabetes on the development progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med . 1993;  329 977-986
    Google Scholar
  • 31 Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive therapy on the development progression of diabetic nephropathy in the Diabetes Control Complications Trial.  Kidney Int . 1995;  47 1703-1720
    PubMedGoogle Scholar
  • 32 United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonilureas or insulin compared with conventional treatment risk of complications in patients with type 2 diabetes.  Lancet . 1998;  352 837-851
    CrossrefPubMedGoogle Scholar
  • 33 Warram J, Cott L, Hanna L. Progression of microalbuminuria to proteinuria in Type 1 diabetes: nonlinear relationship with hyperglycemia.  Diabetes . 2000;  49 94-100
    PubMedGoogle Scholar
  • 34 Klag M, Whelton P, Randall B. Blood pressure end-stage renal disease in men.  N Engl J Med . 1996;  334 13-18
    CrossrefPubMedGoogle Scholar
  • 35 Parving H-H, Andersen A R, Smidt U M, Svendsen P A. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.  Lancet . 1983;  1 1175-1179
    PubMedGoogle Scholar
  • 36 Lewis E, Hunsicker L, Bain R, Rohde R. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy.  N Engl J Med . 1993;  329 1456-1462
    CrossrefPubMedGoogle Scholar
  • 37 Estacio R, Jeffers B, Hiatt W, Biggerstaff S, Giggfford N, Schrier R. The effects of nisoldipine as compared with enalapril on cardiovascualr outcomes in patients with noninsulin-dependent diabetes hypertension. An ACE inhibition on diabetic nephropathy.  N Engl J Med . 1998;  338 645-652
    CrossrefPubMedGoogle Scholar
  • 38 Hansson L, Zanchetti A, Carruthers S G, for the HOT Study Group. Effects of intensive blood pressure lowering low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  Lancet . 1998;  351 1755-1786
    CrossrefPubMedGoogle Scholar
  • 39 Tuomilehto J, Rastenyte D, Birkenhager W, for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes systolic hypertension.  N Engl J Med . 1999;  340 877-884
    PubMedGoogle Scholar
  • 40 Velussi M, Brocco E, Frigato F. Effects of cilazapril amlodipine on kidney function in hypertensive NIDDM patients.  Diabetes . 1996;  45 3216-3222
    PubMedGoogle Scholar
  • 41 Bakris G, Barnhill B, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection.  Kidney Int . 1992;  41 912-919
    PubMedGoogle Scholar
  • 42 Estacio R, Jeffers B, Gifford N, Schrier R. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension type 2 diabetes.  Diabetes Care . 2000;  23 (suppl 2) B54-64
    PubMedGoogle Scholar
  • 42a Lewis W E, Hunsicker L, Clarke W. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.  N Engl J Med . 2001;  345 851-860
    CrossrefPubMedGoogle Scholar
  • 43 Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese V M. Diurnal variations of blood pressure microalbuminuria in essential hypertension.  Am J Hypertens . 1994;  7 23-29
    PubMedGoogle Scholar
  • 44 Vestbo E, Damsgaard E M, Froland A, Mogensen C E. Microalbuminuria in a population-based cohort: ways of expression of albuminuria (Fredericia Study Second Generation).  J Diabetes Complications . 1994;  8 176-177
    CrossrefPubMedGoogle Scholar
  • 45 Cirillo M, Stellato D, Laurenzi M, for The Gubbio Study Collaborative Research Group. Pulse pressure isolated systolic hypertension: association with microalbuminuria.  Kidney Int . 2000;  58 1211-1218
    CrossrefPubMedGoogle Scholar
  • 46 Krolewski A. Genetics of diabetic nephropathy: evidence for major minor gene effects.  Kidney Int . 1999;  55 1582-1596
    CrossrefPubMedGoogle Scholar
  • 47 Faronato P, Maioli M, Tonolo G, Nosadini R. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group.  Diabetologia . 1997;  40 778-783
    CrossrefPubMedGoogle Scholar
  • 48 Pettitt D, Saad M, Bennett P, Nelson R, Knowler W. Familial predisposition to renal disease in two generations of Pima Indians with type 2 diabetes mellitus.  Diabetologia . 1990;  33 438-443
    CrossrefPubMedGoogle Scholar
  • 49 Spielman R S, Mcginnis R, Ewens W. Transmission test for linkage disequilibrium: the insulin gene region insulin-dependent diabetes mellitus.  Am J Human Genet . 1993;  52 506-516
    PubMedGoogle Scholar
  • 50 Spielman R, Ewenes W. A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test.  Am J Human Genet . 1998;  62 450-458
    PubMedGoogle Scholar
  • 51 Krolewski A, Canessa M, Warram J. Predisposition to hypertension susceptibility to renal disease in IDDM.  N Engl J Med . 1988;  318 140-145
    CrossrefPubMedGoogle Scholar
  • 52 Marre M, Jeunemaitre X, Gallois Y. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes.  J Clin Invest . 1997;  99 1585-1595
    PubMedGoogle Scholar
  • 53 Moczulski D, Rogus J, Antonellis A, Warram J, Krolewski A. Major susceptibility locus for nephropathy in type 1 diabetes on chromosome 3q. Results of novel discordant sibpair analysis.  Diabetes . 1998;  47 1164-1169
    PubMedGoogle Scholar
  • 54 Imperatore G, Hanson R, Pettitt D, Kobes S, Bennett P, Knowler W. Sibpair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes mellitus.  Diabetes . 1998;  47 821-830
    PubMedGoogle Scholar
  • 55 Makino H, Sugiyama H, Kashihara N. Apoptosi extracellular matrix-cell interactions in kidney disease.  Kidney Int . 2000;  58 S67-S75
    CrossrefPubMedGoogle Scholar
  • 56 Chen S, Cohen M, Ziyadeh F. Amadori-glycated albumin in diabetic nephropathy. Pathophysiologic connections.  Kidney Int . 2000;  58 S40-S44
    CrossrefPubMedGoogle Scholar
  • 57 Suzuki H, Kurihara Y, Takeya M. A role for macrophage scavenger receptors in atherosclerosis susceptibility to infection.  Nature . 1997;  386 292-296
    CrossrefPubMedGoogle Scholar
  • 58 Padilla O, Calvo J, Vilà J. Genomic organization of the human CD5 gene.  Immunogenetics . 2000;  51 993-1001
    CrossrefPubMedGoogle Scholar
  • 59 Pugliese G, Pricci F, Romeo G. Upregulation of mesangial growth factor extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism.  Diabetes . 1997;  46 1881-1887
    PubMedGoogle Scholar
  • 60 He C, Zheng F, Stitt A, Striker L, Hattori M, Vlassara H. Differential expression of renal AGE-receptor genes in NOD mice: possible role in nonobese diabetic renal disease.  Kidney Int . 2000;  58 1931-1940
    CrossrefPubMedGoogle Scholar
      >